Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
BURLINGTON, Mass., Feb. 26, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth quarter and full year 2017 financial results after the close of the U.S. financial markets on Thursday, March 8, 2018. Flexion’s management will host a conference call at 4:30 p.m. ET to discuss the results and provide an update on business operations.
The dial-in number for the conference call is 1-855-770-0022 for domestic participants and 1-908-982-4677 for international participants, with Conference ID #7699053. A live webcast of the conference call can also be accessed through the "Investors" tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of The Boston Business Journal's 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by The Boston Globe.
Contact:
Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
